The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 22, 2013
Filed:
Sep. 25, 2009
Tomoyuki Igawa, Shizuoka, JP;
Shinya Ishii, Shizuoka, JP;
Atsuhiko Maeda, Shizuoka, JP;
Mika Sakurai, Shizuoka, JP;
Tetsuo Kojima, Shizuoka, JP;
Tatsuhiko Tachibana, Shizuoka, JP;
Hirotake Shiraiwa, Shizuoka, JP;
Hiroyuki Tsunoda, Shizuoka, JP;
Yoshinobu Higuchi, Shizuoka, JP;
Tomoyuki Igawa, Shizuoka, JP;
Shinya Ishii, Shizuoka, JP;
Atsuhiko Maeda, Shizuoka, JP;
Mika Sakurai, Shizuoka, JP;
Tetsuo Kojima, Shizuoka, JP;
Tatsuhiko Tachibana, Shizuoka, JP;
Hirotake Shiraiwa, Shizuoka, JP;
Hiroyuki Tsunoda, Shizuoka, JP;
Yoshinobu Higuchi, Shizuoka, JP;
Chugai Seiyaku Kabushiki Kaisha, Tokyo, JP;
Abstract
The present invention provides pharmaceutical compositions comprising second-generation molecules that are superior than TOCILIZUMAB, by altering the amino acid sequences of the variable and constant regions of TOCILIZUMAB, which is a humanized anti-IL-6 receptor IgG1 antibody, to enhance the antigen-neutralizing ability and increase the pharmacokinetics, so that the therapeutic effect is exerted with a less frequency of administration, and the immunogenicity, safety and physicochemical properties (stability and homogeneity) are improved. The present invention also provides methods for producing these pharmaceutical compositions. The present inventors have successfully generated second-generation molecules that are superior to TOCILIZUMAB by appropriately combining amino acid sequence alterations in the CDR domains, variable regions, and constant regions.